FORT WORTH, Texas, April 23 /PRNewswire/ -- DFB Pharmaceuticals, Inc., has announced the promotion of Maxwell A. Lea, III, to Vice President Business Development and Corporate Finance. Mr. Lea was most recently Director of Corporate Development and Finance for the company.
"Since joining DFB in 2002, Maxwell has positively impacted every level of our company and its affiliate businesses," said Michael A. Patterson, Chief Financial Officer of DFB Pharmaceuticals. "I can say without reservation that our companies have excelled due to his successes."
As Vice President, Mr. Lea will manage DFB's capital raising and financing activities, business development initiatives and strategic planning. He will also be responsible for business development efforts for Healthpoint, Ltd., a DFB affiliate company also based in Fort Worth.
His role for Healthpoint, a branded specialty pharmaceutical company, will be to serve as a member of its senior staff group, managing a team that focuses on further expanding the Healthpoint product portfolio through the acquisition of products and technologies.
Additionally, Mr. Lea has also assumed responsibility for Healthpoint International, with employees in Canada, Puerto Rico and Switzerland and distributors in numerous countries around the globe.
Prior to his career at DFB, Mr. Lea was an investment banker with Banc of America Securities. He received a Bachelor of Arts in Economics from
DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB's business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for wound care indications since 1992. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world's leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in pharmaceutical and biotech industries.
|SOURCE DFB Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved